Search results for "Viral therapy"

showing 10 items of 135 documents

Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: a cross-sectional analysis.

2012

Introduction: This study aimed at defining protease (PR) resistance mutations associated with darunavir (DRV) failure and PR resistance evolution at DRV failure in a large database of treatment-experienced human immunodeficiency virus (HIV) patients. Results: Overall, 1,104 patients were included: 118 (10.7%) failed at a median observation time of 16 months. The mean number of PR mutations at baseline was 2.7, but it was higher in patients who subsequently failed DRV. In addition, the number of PR mutations increased at failure. The increase in the mean number of mutations was completely related to mutations considered to be associated with DRV resistance following the indications of the ma…

MaleTime FactorsCross-sectional studyHuman immunodeficiency virus (HIV)Drug ResistanceHIV InfectionsDrug resistancemedicine.disease_causeCohort StudiesAntiretroviral Therapy Highly ActiveRitonavir-boosted darunavirGenotypeHIV InfectionTreatment FailureViralGenotypic resistanceDarunavirSulfonamidesGeneral MedicineMiddle AgedVirological failureInfectious DiseasesFemaleHumanmedicine.drugAdultMicrobiology (medical)Logistic ModelTime FactorGenotypeAntiretroviral TherapySettore MED/17 - MALATTIE INFETTIVESulfonamideDrug Resistance ViralmedicineHumansHighly ActiveDarunavir; Genotypic resistance; Protease inhibitors; Ritonavir-boosted darunavir; Adult; Antiretroviral Therapy Highly Active; Cohort Studies; Cross-Sectional Studies; Female; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Logistic Models; Male; Middle Aged; Mutation; Sulfonamides; Time Factors; Treatment Failure; Drug Resistance Viral; Microbiology (medical); Infectious DiseasesHIV Protease InhibitorDarunavirCross-Sectional Studiebusiness.industryHIV Protease InhibitorsProtease inhibitorsAntiretroviral therapyVirologyCross-Sectional StudiesLogistic ModelsProtease inhibitorMutationGenotypic resistanceHIV-1Cohort Studiebusiness
researchProduct

Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort

2019

Introduction: Concerns about dolutegravir (DTG) tolerability in the real-life setting have recently arisen. We aimed to estimate the risk of treatment discontinuation and virological failure of DTG-based regimens from a large cohort of HIV-infected individuals. Methods: We performed a multicentre, observational study including all antiretroviral therapy (ART)-naïve and virologically suppressed treatment-experienced (TE) patients from the Icona (Italian Cohort Naïve Antiretrovirals) cohort who started, for the first time, a DTG-based regimen from January 2015 to December 2017. We estimated the cumulative risk of DTG discontinuation regardless of the reason and for toxicity, and of virologica…

Maleadverse eventadverse events; antiretroviral therapy; cohort study; discontinuation; dolutegravir; toxicity; Adult; Anti-HIV Agents; Cohort Studies; Dideoxynucleosides; Female; HIV Infections; Heterocyclic Compounds 3-Ring; Humans; Italy; Male; Middle Aged; Prospective Studies; Retrospective Studies; Tenofovir; Treatment Outcomeadverse events; antiretroviral therapy; cohort study; discontinuation; dolutegravir; toxicity;HIV InfectionsPiperazinesCohort Studies0302 clinical medicineHeterocyclic CompoundsAbacavirRetrospective StudieMedicineHIV InfectionProspective Studies030212 general & internal medicineProspective cohort studyResearch Articlesadverse events; antiretroviral therapy; cohort study; discontinuation; dolutegravir; toxicityHazard ratioMiddle AgedDideoxynucleosidedolutegravirTreatment OutcomeInfectious DiseasesTolerabilityItalyCohortFemalePublic Health0305 other medical scienceHeterocyclic Compounds 3-RingResearch Articlemedicine.drugHumanAdultmedicine.medical_specialtyAnti-HIV AgentsPyridonesantiretroviral therapySettore MED/17 - MALATTIE INFETTIVE3-RingLower riskNO03 medical and health sciencesInternal medicineOxazinescohort studyHumansTenofovirRetrospective Studies030505 public healthbusiness.industryEnvironmental and Occupational HealthPublic Health Environmental and Occupational HealthAnti-HIV AgenttoxicityRetrospective cohort studyantiretroviral therapy; dolutegravir; cohort study; discontinuation; toxicity; adverse eventsDideoxynucleosidesadverse eventsDiscontinuationProspective Studieadverse events; antiretroviral therapy; cohort study; discontinuation; dolutegravir; toxicity; Public Health Environmental and Occupational Health; Infectious DiseasesCohort Studiebusinessdiscontinuation
researchProduct

Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy

2009

Treatment with peginterferon alfa and ribavirin produces a sustained virologic response (SVR) in approximately 60% of hepatitis C virus (HCV)-infected patients. Alternate options are needed for patients who relapse or do not respond to therapy.This prospective, international, multicenter, open-label study evaluated efficacy and safety of peginterferon alfa-2b (1.5 microg/kg/wk) plus weight-based ribavirin (800-1400 mg/day) in 2333 chronic HCV-infected patients with significant fibrosis/cirrhosis whose previous interferon alfa/ribavirin therapy failed. Patients with undetectable HCV-RNA at treatment week (TW) 12 received 48 weeks of therapy; patients with detectable HCV-RNA at TW12 could ent…

Malemedicine.medical_specialtyHepatitis C virusPeginterferon-alfaHepacivirusInterferon alpha-2medicine.disease_causeAntiviral AgentsGastroenterologyPolyethylene Glycolschemistry.chemical_compoundPharmacotherapyInternal medicineRibavirinmedicineHCV ANTIVIRAL THERAPYHumansTreatment FailureInterferon alfaHepatologybusiness.industryRibavirinGastroenterologyInterferon-alphavirus diseasesHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseRecombinant Proteinsdigestive system diseaseschemistryImmunologyRNA ViralPeginterferon alfa-2bDrug Therapy CombinationFemalebusinessViral loadmedicine.drug
researchProduct

Morphological analysis of the skeletal development in lateral cephalometric radiographs of HIV infected children ongoing Highly Active Antiretroviral…

2018

Background To investigate the skeletal development of HIV infected children through a morphological analysis of the cervical vertebrae (CV) in lateral cephalometric radiographs. Material and Methods The sample consisted of 86 lateral cephalometric radiographs of male and female children aged between 6 and 14 years old. The radiographs were equally distributed in groups 1 (HIV infected children) and 2 (non-infected children, paired by sex and age). Two examiners analyzed the CV according to the method of Hassel and Farman (1995). Spearman correlation coefficient was used to associate age and skeletal development within groups, while Mann-Whitney test compared the skeletal development between…

Malemedicine.medical_specialtyORTHODONTIC PROCEDURESAdolescentCephalometryRadiographyDentistryHIV Infections03 medical and health sciences0302 clinical medicineAntiretroviral Therapy Highly ActiveHiv infectedmedicineHumans030212 general & internal medicineChildGeneral DentistryBone Developmentbusiness.industryResearch030206 dentistryCraniometryMedically compromised patients in Dentistry:CIENCIAS MÉDICAS [UNESCO]Antiretroviral therapyRadiographymedicine.anatomical_structureOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASOrthopedic surgeryMorphological analysisCervical VertebraeFemaleSurgerybusinessCervical vertebraeMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Assessment of hepatitis C virus-RNA clearance under combination therapy for hepatitis C virus genotype 1: performance of transcription-mediated ampli…

2007

Monitoring of HCV-RNA in blood during antiviral therapy is performed mostly by commercially available reverse transcription polymerase chain reaction-based (RT-PCR) assays, with a lower detection limit of 30-50 IU/mL of HCV-RNA. Use of different tests in the pivotal trials of combination therapy has generated some discordance, in terms of predictive value of the early virological response (EVR). To evaluate whether the use of a more sensitive test, as a qualitative assay based on transcription mediated amplification (TMA) with a lower detection limit of 5-10 IU/mL of HCV-RNA, may obtain a better prediction of EVR and of the ultimate virological outcome, we retrospectively evaluated serial s…

Malemedicine.medical_specialtySettore MED/07 - Microbiologia E Microbiologia ClinicaSettore MED/09 - Medicina InternaCombination therapyGenotypeTranscription GeneticTranscription-mediated amplificationHepacivirusAlpha interferonHepacivirusInterferon alpha-2GastroenterologyAntiviral AgentsSensitivity and Specificityantiviral therapy EVR HCV chronic hepatitis HCV-RNA RT-PCR TMAPolyethylene Glycolschemistry.chemical_compoundInterferonPredictive Value of TestsVirologyInternal medicineRibavirinmedicineHumansRetrospective StudiesSettore MED/12 - GastroenterologiaHepatologybiologybusiness.industryReverse Transcriptase Polymerase Chain ReactionRibavirinInterferon-alphaNucleic acid amplification techniqueHepatitis C Chronicbiology.organism_classificationVirologydigestive system diseasesRecombinant ProteinsInfectious DiseasesReal-time polymerase chain reactionTreatment OutcomechemistryRNA ViralDrug Therapy CombinationFemalebusinessNucleic Acid Amplification Techniquesmedicine.drug
researchProduct

Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Ev…

2021

Background: Chronic hepatitis C (CHC) is associated with hepatic steatosis, related to both a direct viral action and metabolic features. Vice-versa data on hepatic steatosis after viral eradication by direct-acting antiviral agents (DAA) are undefined although the presence of metabolic alterations could strongly influence the occurrence of steatosis as in NAFLD. The controlled attenuation parameter (CAP) (FibroscanⓇ) allows the qualitative and quantitative evaluation of fatty liver. Aim: to evaluate in patients with CHC whether hepatic steatosis diagnosed by CAP modifies after DAAs-induced sustained virologic response (SVR). Methods: Data were collected the day of DAAs therapy starting and…

Malemedicine.medical_specialtySustained Virologic ResponseOverweightGastroenterologyAntiviral Agents03 medical and health sciences0302 clinical medicineChronic hepatitisInternal medicineGenotypemedicineHumansDe novo steatosiDAAAgedRetrospective StudiesHypertriglyceridemiaHepatologybusiness.industryFatty liverHypertriglyceridemiaGastroenterologyAntiviral therapyOverweightHepatitis C ChronicMiddle Agedmedicine.diseaseMale sexFatty LiverSVR.Italy030220 oncology & carcinogenesisHCV030211 gastroenterology & hepatologyFemalemedicine.symptomSteatosisbusinessDirect actingDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Genomic medicine reaches HCV-related liver transplantation: Hopes and clinical and public health implications

2011

Malemedicine.medical_specialtymedicine.medical_treatmentIL28BOLTLiver transplantationAntiviral therapyBioinformaticsHepatitismedicineHumansGenomic medicineHepatitisHepatologybusiness.industryInterleukinsPublic healthAntiviral therapyHepatitis C Chronicmedicine.diseaseLiver TransplantationImmunologyHCVInterferonFemaleInterferonsbusiness
researchProduct

Recent acquired STD and the use of HAART in the Italian Cohort of Naive for Antiretrovirals (I.Co.N.A): analysis of the incidence of newly acquired h…

2008

Objective: To estimate the incidence of newly acquired syphilis (n-syphilis) and hepatitis B infection (n-hepatitis B) in I.Co.N.A. and to evaluate the impact of HAART, calendar date and risk group. Methods: Cohort study: Incidence was calculated by person-years analyses. Poisson regression was used for the multivariate model. Results: The rate of n-syphilis was 23.4/1,000 PYFU and it increased over time; HIV transmission risk was the most important predictor: men who have sex with men (MSM) had a considerable higher risk (RR 5.92, 95% CI 2.95-12.13 vs IDU/exIDU, p < 0.0001). The rate of n-hepatitis B was 12.2/1,000 PYFU; it declined in recent years and halved per 10 years age. Patients wit…

Microbiology (medical)AdultMalemedicine.medical_specialtyHBsAgHAARTPopulationImmunologySexually Transmitted DiseasesHIV InfectionsLower riskRegression AnalysiMen who have sex with menCohort StudiesAcquired immunodeficiency syndrome (AIDS)Internal medicineAntiretroviral Therapy Highly ActivemedicineHumansHIV InfectionPoisson DistributionSyphilisHomosexuality MaleeducationMultivariate AnalysiSexually Transmitted Diseaseeducation.field_of_studybusiness.industryIncidence (epidemiology)Incidencevirus diseasesHIVGeneral MedicineHepatitis Bmedicine.diseaseHepatitis BInfectious DiseasesSyphiliItalyImmunologyCohortMultivariate AnalysisHIV-1Regression AnalysisFemaleCohort StudiebusinessHumanInfection
researchProduct

Cytomegalovirus Infection Management in Allogeneic Stem Cell Transplant Recipients: a National Survey in Spain.

2015

ABSTRACT This study gathered information about current practices of cytomegalovirus (CMV) infection management in allogeneic stem cell transplant recipients at Spanish centers. A wide variety of preemptive antiviral therapy strategies for CMV infection guided by real-time PCR assays was found, yet the incidence of CMV disease was low (&lt;3%).

Microbiology (medical)AdultPcr assayCongenital cytomegalovirus infectionReal-Time Polymerase Chain ReactionAntiviral AgentsChemopreventionVirologyMedicineHumansTransplantation Homologousbusiness.industryIncidence (epidemiology)Antiviral therapyvirus diseasesCase managementmedicine.diseaseCytomegalovirus infectionTransplantationMolecular Diagnostic TechniquesSpainImmunologyCytomegalovirus InfectionsStem cellbusinessCase ManagementStem Cell Transplantation
researchProduct

Effect of antiretroviral protease inhibitors alone, and in combination with paromomycin, on the excystation, invasion and in vitro development of Cry…

2003

With the spread of the human immunodeficiency virus in the early 1980s, cryptosporidiosis was regarded as an AIDS-defining disease. As an opportunistic pathogen, the intestinal parasite Cryptosporidium parvum became an important cause of chronic diarrhoea, leading to high morbidity and mortality in immunocompromised patients. To date, no effective chemotherapy is available. With the introduction of protease inhibitors (PIs) in highly active antiretroviral therapy (HAART), the incidence of cryptosporidiosis in AIDS patients has declined substantially in western countries. We have therefore tested the effect of five PIs used in HAART on the excystation, invasion and development of the parasit…

Microbiology (medical)Cell SurvivalParomomycinvirusesCryptosporidiosisParomomycinHost-Parasite InteractionsMicrobiologyImmunoenzyme Techniquesimmune system diseasesIndinavirAntiretroviral Therapy Highly ActiveCell Line TumormedicineAnimalsHumansPharmacology (medical)Protease inhibitor (pharmacology)AmebicidesAntibacterial agentCryptosporidium parvumPharmacologybiologyvirus diseasesDrug SynergismHIV Protease Inhibitorsbiochemical phenomena metabolism and nutritionbiology.organism_classificationVirologyInfectious DiseasesCryptosporidium parvumNelfinavirRitonavirSaquinavirmedicine.drugJournal of Antimicrobial Chemotherapy
researchProduct